MARKET

BIO-B

BIO-B

BIO RAD LABORATO
NYSE

Real-time Quotes | Nasdaq Last Sale

788.75
0.00
0.00%
Closed 15:50 09/22 EDT
OPEN
--
PREV CLOSE
818.60
HIGH
--
LOW
--
VOLUME
16
TURNOVER
--
52 WEEK HIGH
826.65
52 WEEK LOW
508.00
MARKET CAP
23.48B
P/E (TTM)
5.88
1D
5D
1M
3M
1Y
5Y
BRIEF-Bio-Rad Reports Q2 2021 Financial Results
reuters.com · 07/29 20:50
Bio-Rad, 10x Genomics settle genomics patent war
Rivals Bio-Rad Laboratories Inc and 10x Genomics Inc have settled their multi-front battle over microfluidic genetic analysis technology, 10x announced Tuesday.
Reuters · 07/27 19:39
BRIEF-Bio-Rad And 10X Genomics Announce Settlement To Resolve Multiple Litigations
reuters.com · 07/27 16:32
BRIEF-10X Genomics Inc Says Entered Into A Global Settlement And Cross-License Agreement With Bio-Rad Laboratories, Inc
reuters.com · 07/27 11:44
BRIEF-10X Genomics Signs Global Patent Cross License Agreement With Bio-Rad
reuters.com · 07/27 10:36
Bio-Rad, Harvard settle DNA analysis patent dispute with French company
Bio-Rad Laboratories has settled its patent infringement claims against French biotech company Stilla Technologies three days after the start of a trial in Boston federal court, according to a court filing.
Reuters · 07/08 21:26
BRIEF-Bio-Rad Announces Partnership With Seegene For Molecular Diagnostic Testing Products
reuters.com · 06/30 21:04
Fed Circ affirms mixed ITC ruling in 10x and Bio-Rad's patent fight
The U.S. Court of Appeals for the Federal Circuit affirmed an International Trade Commission ruling Friday that some genetic-analysis products imported by 10x Genomics Inc infringe rival Bio-Rad Laboratories Inc's patents.
Reuters · 05/28 22:29
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BIO-B. Analyze the recent business situations of BIO RAD LABORATO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.64%
Healthcare Equipment & Supplies
+0.81%
Key Executives
Chairman/President/Chief Executive Officer/Director
Norman Schwartz
Chief Financial Officer/Executive Vice President
Ilan Daskal
Chief Operating Officer/Executive Vice President
Andrew Last
Executive Vice President/General Counsel/Secretary
Timothy Ernst
Executive Vice President
Michael Crowley
Executive Vice President
Giovanni Magni
Executive Vice President
Annette Tumolo
Executive Vice President
Dara Wright
Vice President/Treasurer
Ronald Hutton
Lead Director/Independent Director
Gregory Hinckley
Director
Alice Schwartz
Independent Director
Jeffrey Edwards
Independent Director
Melinda Litherland
Independent Director
Arnold Pinkston
No Data
About BIO-B
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.

Webull offers kinds of Bio-Rad Laboratories, Inc. stock information, including NYSE:BIO B real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIO B stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIO-B stock methods without spending real money on the virtual paper trading platform.